Updating Photon-Based Normal Tissue Complication Probability Models for Pneumonitis in Patients With Lung Cancer Treated With Proton Beam Therapy

Torre, 2016, Lung cancer statistics, Adv Exp Med Biol, 893, 1, 10.1007/978-3-319-24223-1_1 Siegel, 2019, Cancer statistics, 2019, CA Cancer J Clin, 69, 7, 10.3322/caac.21551 Noone AM, Howlader N, Krapcho M, et al (eds). Cancer Statistics Review, 1975-2015 - SEER Statistics. SEER Cancer Statistics Review. Available at: https://seer.cancer.gov/csr/1975_2015/. Accessed January 1, 2020. Antonia, 2018, Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC, N Engl J Med, 379, 2342, 10.1056/NEJMoa1809697 Simone, 2017, Thoracic radiation normal tissue injury, Semin Radiat Oncol, 27, 370, 10.1016/j.semradonc.2017.04.009 Rodrigues, 2004, Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer - A systematic review, Radiother Oncol, 71, 127, 10.1016/j.radonc.2004.02.015 Graves, 2010, Radiation pulmonary toxicity: From mechanisms to management, Semin Radiat Oncol, 20, 201, 10.1016/j.semradonc.2010.01.010 Mehta, 2005, Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: Pulmonary function, prediction, and prevention, Int J Radiat Oncol Biol Phys, 63, 5, 10.1016/j.ijrobp.2005.03.047 Vogelius, 2013, A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis, Anta Oncol, 51, 975 Gray JE, Villegas A, Daniel D, et al. Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC—Update from PACIFIC. J Thorac Oncol. https://doi.org/10.1016/j.jtho.2019.10.002. Giaddui T, Chen W, Yu J, et al. Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: Phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC. Radiat Oncol. https://doi.org/10.1186/s13014-016-0640-8. Liao Z, Lee JJ, Komaki R, et al. Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non–small-cell lung cancer. J Clin Oncol. https://doi.org/10.1200/JCO.2017.74.0720. Yorke ED. Parameters for and use of NTCP models in the clinic The 1991 Data Set 1991 to Now. Ppt.:1-8. Available at: https://www.aapm.org/meetings/amos2/pdf/29-7787-23771-420.pdf. Accessed June 24, 2020. Marks, 2010, Radiation dose volume effects in the lung, Int J Radiat Oncol Biol Phys, 76, 70, 10.1016/j.ijrobp.2009.06.091 Appelt, 2014, Towards individualized dose constraints: Adjusting the QUANTEC radiation pneumonitis model for clinical risk factors, Acta Oncol (Madr), 53, 605, 10.3109/0284186X.2013.820341 Seppenwoolde, 2003, Comparing different NTCP models that predict the incidence of radiation pneumonitis, Int J Radiat Oncol Biol Phys, 55, 724, 10.1016/S0360-3016(02)03986-X Tsougos, 2007, NTCP modelling and pulmonary function tests evaluation for the prediction of radiation induced pneumonitis in non-small-cell lung cancer radiotherapy, Phys Med Biol, 52, 1055, 10.1088/0031-9155/52/4/013 Semenenko, 2008, Lyman-Kutcher-Burman NTCP model parameters for radiation pneumonitis and xerostomia based on combined analysis of published clinical data, Phys Med Biol, 53, 737, 10.1088/0031-9155/53/3/014 Hong, 1996, A pencil beam algorithm for proton dose calculations, Phys Med Biol, 41, 1305, 10.1088/0031-9155/41/8/005 2007 Paganetti, 2002, Relative biological effectiveness (RBE) values for proton beam therapy, Int J Radiat Oncol Biol Phys, 53, 407, 10.1016/S0360-3016(02)02754-2 Veiga, 2016, First clinical investigation of cone beam computed tomography and deformable registration for adaptive proton therapy for lung cancer, Int J Radiat Oncol Biol Phys, 95, 549, 10.1016/j.ijrobp.2016.01.055 Van Der Schaaf, 2017, Updating QUANTEC and clinically adjusted QUANTEC models for pneumonitis at external validation, Radiother Oncol, 123, S68, 10.1016/S0167-8140(17)30583-2 Vergouwe, 2017, A closed testing procedure to select an appropriate method for updating prediction models, Stat Med, 36, 4529, 10.1002/sim.7179 Brodin, 2018, Systematic review of normal tissue complication models relevant to standard fractionation radiation therapy of the head and neck region published after the QUANTEC reports, Int J Radiat Oncol Biol Phys, 100, 391, 10.1016/j.ijrobp.2017.09.041 Marks, 2015, Radiation dose–volume effects in the lung, Int J Radiat Oncol Biol Phys, 76, S20 Yamada, 1998, Risk factors of pneumonitis following chemoradiotherapy for lung cancer, Eur J Cancer, 34, 71, 10.1016/S0959-8049(97)00377-8 Leprieur, 2013, Acute radiation pneumonitis after conformational radiotherapy for nonsmall cell lung cancer: Clinical, dosimetric, and associated-treatment risk factors, J Cancer Res Ther, 9, 447, 10.4103/0973-1482.119339 Langendijk, 2013, Selection of patients for radiotherapy with protons aiming at reduction of side effects: The model-based approach, Radiother Oncol, 107, 267, 10.1016/j.radonc.2013.05.007 Lambin, 2017, Decision support systems for personalized and participative radiation oncology, Adv Drug Deliv Rev, 109, 131, 10.1016/j.addr.2016.01.006